Internal link ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP Juni 26, 2025 at 08:30 PM UTC
Internal link ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences Mai 12, 2025 at 12:00 PM UTC
Internal link ProQR Announces First Quarter 2025 Operating and Financial Results Mai 08, 2025 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference Mai 02, 2025 at 12:00 PM UTC
Internal link ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025 Mai 01, 2025 at 12:00 PM UTC
Internal link ProQR Strengthens Leadership with Appointments of CFO and CMO to Support Next Phase of Growth April 14, 2025 at 11:00 AM UTC
Internal link ProQR Announces Year End 2024 Operating and Financial Results März 13, 2025 at 11:00 AM UTC
Internal link ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets Dezember 08, 2023 at 12:30 PM UTC
Internal link ProQR Announces Third Quarter 2023 Operating and Financial Results November 07, 2023 at 12:00 PM UTC
Internal link ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing November 06, 2023 at 12:00 PM UTC
Internal link ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference September 28, 2023 at 12:00 PM UTC
Internal link ProQR Therapeutics Provides Update on Ophthalmic Assets September 27, 2023 at 11:00 AM UTC
Internal link ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference September 07, 2023 at 12:00 PM UTC
Internal link ProQR Announces Second Quarter 2023 Operating and Financial Results August 03, 2023 at 11:00 AM UTC
Internal link ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets August 01, 2023 at 11:00 AM UTC
Internal link ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit Juli 06, 2023 at 11:00 AM UTC
Internal link ProQR Announces First Quarter 2023 Operating and Financial Results Mai 16, 2023 at 11:00 AM UTC
Internal link ProQR to Present its Axiomer® RNA Editing Technology at TIDES USA 2023 Mai 09, 2023 at 12:00 PM UTC
Internal link ProQR Announces Upcoming Investor Conferences in April and May April 20, 2023 at 12:00 PM UTC
Internal link ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023 April 18, 2023 at 12:00 PM UTC
Internal link ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event März 29, 2023 at 12:00 PM UTC
Internal link ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing März 14, 2023 at 12:00 PM UTC
Internal link ProQR to Present at Upcoming Scientific and Industry Conferences März 07, 2023 at 01:00 PM UTC
Internal link ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023 Februar 28, 2023 at 01:00 PM UTC
Internal link ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital Dezember 30, 2021 at 12:00 PM UTC